Brief: Hansa Biopharma And Partner Sarepta Therapeutics Plan To Initiate A Clinical Study With Imlifidase As A Pre-Treatment To Sarepta's SRP-9001 Gene Therapy In DMD In 2023
03/11/2022 03:04
Nov 2 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA AND PARTNER SAREPTA THERAPEUTICS PLAN TO
INITIATE A CLINICAL STUDY WITH IMLIFIDASE AS A PRE-TREATMENT TO
SAREPTA'S SRP-9001 GENE THERAPY IN DMD IN 2023
Source text for Eikon: ID:nPn83ZGn3a
Further company coverage: HNSA.ST
((reuters.briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS